The strongest result first
Ipamorelin Isn't Approved Medicine
One published trial tested whether patients improved. The drug didn't show a clear benefit, and approval never followed.
Surgery patients got no clear benefit from Ipamorelin
After bowel surgery, patients were timed until they could eat. Ipamorelin didn't shorten that wait clearly enough to rule out chance [3]. That's the best human test available. No health office has approved the drug as medicine.
Ipamorelin links five protein building blocks. Scientists made it in the 1990s to release growth hormone [1]. It did so without raising cortisol, the hormone your body releases under stress.
That finding shows an effect, not better health. People who tried research powder report sleep, recovery, flushing, and hunger changes. Those stories aren't fair tests and can't settle the claims. Read the Ipamorelin effects with that warning in mind.
Ipamorelin makes the pituitary release growth hormone
Scientists first described this five-part drug in the 1990s [1]. The pituitary is a pea-sized gland beneath the brain. Ipamorelin tells it to send growth hormone into the blood. It attaches where ghrelin, your hunger hormone, attaches to pituitary cells [1].
A 1998 study compared ipamorelin with older lab drugs called peptide 6 and peptide 2. In pigs, peptide 6 raised growth hormone. Researchers also watched whether peptide 6 changed cortisol.
Growth hormone went up, while cortisol stayed flat. Cortisol stayed level even when researchers gave over 200 times the working amount [1]. That doesn't mean the high amount was safe; it only describes one test.
Ipamorelin isn't the online "CJC-1295 and ipamorelin" pair. That pair includes a second lab-made drug. This page deals with ipamorelin on its own.
Approval never followed the failed Ipamorelin trial
The U.S. Food and Drug Administration has never approved ipamorelin [3]. Europe's drug office hasn't approved it either. The later Phase 2 trial, a mid-stage test, enrolled 114 adults after bowel surgery.
Patients on ipamorelin ate sooner than patients given a placebo. A placebo has the look of treatment but no active drug. Chance could still explain the difference [3]. That Phase 2 result led to no larger trial.
Pharmacy access narrowed in 2024. A federal panel reviewed ipamorelin on October 29, 2024 [3]. Before removal, the temporary list let pharmacies seek to use it as an ingredient in medicine made for one patient.
Athletes are barred from using ipamorelin at any time. Urine tests can find the drug [7][8][9]. The is ipamorelin fda approved page explains how those rules affect you and a clinic.
Small tests leave safety and benefit unsettled
A vein drip gave healthy men ipamorelin. About half had left their blood within 2 hours. Growth hormone peaked around 40 minutes [2]. Untreated female rats grew 42 millionths of a metre of new bone each day.
At the largest amount, rat bone grew 52 millionths of a metre each day. A liver protein called insulin-like growth factor 1, which helps tissue grow, stayed level [4]. In 2024, ipamorelin cut weight loss in ferrets on cancer treatment by about 24%, but nausea didn't ease [5].
The useful findings come with large gaps. No final Phase 3 trial or long human safety test has finished [3]. During a 28-day test, another drug harmed rat heart muscle [6].
That rat harm doesn't prove ipamorelin hurts the heart. It gives you a fair reason for care. The Ipamorelin research page separates human tests from animal clues.